» Articles » PMID: 23247480

Differential Expression of Programmed Death-1 (PD-1) in Sézary Syndrome and Mycosis Fungoides

Overview
Journal Arch Dermatol
Specialty Dermatology
Date 2012 Dec 19
PMID 23247480
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

OBJECTIVE To determine if there are differences in the expression of programmed death-1 (PD-1) between SS and MF, and in particular erythrodermic MF (E-MF). PD-1 is a marker of follicular helper T (TFH) cells and is expressed by the neoplastic T cells of some types of malignant T-cell lymphoma, including mycosis fungoides (MF) and Sézary syndrome (SS). Reported results of PD-1 staining in MF and SS are, however, conflicting. DESIGN Formalin-fixed, paraffin-embedded skin biopsy specimens were stained for PD-1. In addition, PD-1+ cases were stained with antibodies against BCL6, CXCL13, and CD10 to find possible relationship with TFH cells. SETTING Tertiary referral center for cutaneous lymphomas. PATIENTS Twenty-seven patients with SS and 60 patients with MF, including 8 patients with E-MF. RESULTS In patients with SS, expression of PD-1 by more than 50% of the neoplastic T cells was observed in 24 of 27 cases (89%). In contrast, PD-1 expression by more than 50% of neoplastic T cells was found in only 8 of 60 patients with MF (13%), including only 1 of 8 patients with E-MF (12%). In PD-1+ cases, serial skin sections showed that CXCL13 and BCL6 generally stained 25% to 50% of the PD-1+ cells, while expression of CD10 was uncommon. CONCLUSION The results of the present study show differential expression of PD-1 between SS and MF/E-MF, which provides further support for the view that SS and MF are distinct entities.

Citing Articles

[Differential diagnosis of epidermotropic neoplasia].

Moritz R, Ghoreschi F Dermatologie (Heidelb). 2025; 76(3):140-151.

PMID: 39961813 DOI: 10.1007/s00105-025-05470-8.


Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL).

Case K, Allen P Curr Hematol Malig Rep. 2025; 20(1):5.

PMID: 39800801 DOI: 10.1007/s11899-024-00746-7.


Targeting TAG-72 in cutaneous T cell lymphoma.

Evtimov V, Hammett M, Pupovac A, Nguyen N, Shu R, Van Der Weyden C Heliyon. 2024; 10(17):e36298.

PMID: 39263154 PMC: 11386021. DOI: 10.1016/j.heliyon.2024.e36298.


Tumor flare reaction in a patient with mycosis fungoides treated with a novel immune-epigenetic doublet.

Dar N, Roberts N, Gru A, Obiorah I, Zheng J, Kostakoglu Shields L JAAD Case Rep. 2024; 48:18-22.

PMID: 38741658 PMC: 11090057. DOI: 10.1016/j.jdcr.2024.03.016.


Assessment of PD-1 and PD-L1 tissue expression levels in lichen planus patients: a case-control study.

Elmasry M, Mosaad R, Azzam O, Rashed L, Fahim A Arch Dermatol Res. 2024; 316(3):97.

PMID: 38430309 PMC: 10908618. DOI: 10.1007/s00403-024-02838-z.